Vivox is dedicated to support and promote medical oriented companies to cross their pre-clinical stages for successful FDA, IND application, we are honored to share our pre-clinical services and knowledge both in-vivo and in-vitro with our clients in order to advance potential new therapies towards clinical stages and beyond
Our team of experts will walk you through all the stages, from planning to results
excellency is our goal and form in every step we make
With years of experience, our team can do any work required with the highest reliability
Including our in-vitro and in-vivo departments
Received PhD in Neuro-Immunology from the Weizmann institute of science. During his PhD, he conducted numerous experiments elucidating the role of the blood cerebrospinal fluid barrier as a phenotype-educative gate for beneficial M2 macrophages in the model of spinal cord injury (SCI). During his studies, Omer mastered several in-vivo mice models including transient and permanent middle cerebral artery occlusion (MCAO), SCI, splenectomy and autoimmune uveitis. Also, Omer developed and mastered a unique in-vivo procedure to aspire clean cerebrospinal fluid (CSF) from mice. Since he graduated, Omer served as the CTO of a leading pre-cro company aka Science in action LTD. He designed and executed tremendous amount of experiments to support companies from early stages of pre-clinical work to the demonstration of proof of concept in the relevant animal models. Omer gained vast expertise in various in-vivo animal models as well as complicated microsurgeries.
Ely received his MA in Psycho–Biology from the Tel – Aviv University in Israel. During his studies, Ely focused on Neuro-Immune Communication mediated via physiological stress response. He examined these effects on cancer metastatic process. Since he completed his studies, Ely joined a leading preclinical research company in Israel as a study director and a scientist. As part of his job, Ely specialized in protocols design and writing for efficacy experiments. He worked in close contact with the health department to ensure and approve the studies. Over the last seven years, Ely expertise in developing, designing and conducting several animal models to mimic human diseases and syndromes like Parkinson, Cancer, Diabetic, Coagulation disorders, Intratracheal Autoimmune conditions and more.
Haviva received her M.Sc. in biology from the University of Haifa. Mrs. Nodelman has over 9 years in the Biotechnology industry. Before joining Vivox, she worked as a QC analyst for 5 years in Protalix (FDA approval) and gained great knowledge and skills working in a GMP environment. Haviva brings to VIVOX a wide experience in molecular biology, biochemistry, Immunology, Cell culture and microbiological methods, as well as experience in method development and validations.
Noa received her B.Sc. in biochemistry and food science from the Hebrew University, and has been over 4 years in the pre-clinical services. Before joining Vivox, she worked at the neurobiology department at the Weizmann Institute of Science, gaining experience in writing protocols, accurate laboratory work and working with rodents. Also, Noa has over 8 years of experience in GIS.
Weilin received his PhD from the University Medical Center Groningen (UMCG), the Netherlands, in 2016. His PhD work focus on dissecting molecular mechanisms of metabolism and metabolic diseases, including obesity, Type 2 diabetes and fatty liver disease, by using various rodent models (ob/ob, Cre-Loxp KO and HFD or CDAA dietary induction). In his subsequent research, Weilin has led and developed projects to study the association of cellular senescence and metabolic stresses with cancer development. Personally, Weilin strongly believes multidisciplinary studies combing specialties from different research fields is a key to further understanding of diseases and to develop novel therapies for a better quality of life. During his work, Weilin has established broad network with biological professionals and experts at different research institutes and industrial enterprises, especially in Western Europe and China. His Sino-European experience enable him deep understanding on how procedures and modes of action work in both sides. In the late of 2019, he joined VIVOX as an international project developer (voluntarily) to further bridge VIVOX with other bio-entities to develop and creating new entrepreneurship together.